Presentation TCT 2013 Platelet Function Testing is of Clear Clinical Utility in Selected Patients Presenter: Paul Gurbel October 31, 2013 REGISTER for free or LOG IN to view this content CAD Pharma Presentation TCT 2013 Up Next Presentation TCT 2013 Value Based Purchasing and PCI Presenter: Ty Gluckman October 31, 2013 More slides + Presentation TCT 2013 Optimal DAPT Duration Is Not Established: For Now Most Patients Should Stay on DAPT for at Least One Year! Presenter: Edoardo Camenzind October 31, 2013 Presentation TCT 2013 FREEDOM: A Prospective, Randomized Trial of First Generation Drug-Eluting Stents vs. CABG in Insulin- and Noninsulin-Treated Diabetic Patients Presenter: George Dangas October 31, 2013 We Recommend
Presentation TCT 2013 Optimal DAPT Duration Is Not Established: For Now Most Patients Should Stay on DAPT for at Least One Year! Presenter: Edoardo Camenzind October 31, 2013
Presentation TCT 2013 FREEDOM: A Prospective, Randomized Trial of First Generation Drug-Eluting Stents vs. CABG in Insulin- and Noninsulin-Treated Diabetic Patients Presenter: George Dangas October 31, 2013